作者:A. S. Kulikov、M. A. Epishina、L. V. Batog、V. Yu. Rozhkov、N. N. Makhova、L. D. Konyushkin、M. N. Semenova、V. V. Semenov
DOI:10.1007/s11172-013-0113-2
日期:2013.3
A method of 3-amino-4-[5-aryl(heteroaryl)-1H-1,2,3-triazol-1-yl)]furazan synthesis was optimized. Condensation of these compounds with 2,5-dimethoxytetrahydrofuran resulted in a series of previously unknown 4-[5-aryl(heteroaryl)-1H-1,2,3-triazol-1-yl)]-3-(pyrrol-1-yl)furazans. All target compounds were evaluated for both antimitotic microtubule destabilizing effect in a phenotypic sea urchin embryo assay and cytotoxicity in a panel of 60 human cancer cell lines. Pyrrolyl derivatives of triazolylfurazans were determined as antiproliferative compounds. The most potent microtubule targeting compounds 7a and 7e are of interest for further trials as antineoplastic agents.
优化了3-氨基-4-[5-芳基(杂芳基)-1H-1,2,3-三唑-1-基]呋咱的合成方法。将这些化合物与2,5-二甲氧基四氢呋喃缩合,得到了一系列先前未知的4-[5-芳基(杂芳基)-1H-1,2,3-三唑-1-基]-3-(吡咯-1-基)呋咱。所有目标化合物均在表型海胆胚胎试验中评估了其抗有丝分裂微管解聚效应,并在60种人类癌细胞系中评估了其细胞毒性。确定三唑基呋咱的吡咯基衍生物为抗增殖化合物。最具效力的微管靶向化合物7a和7e值得进一步试验作为抗肿瘤药物。